TSPAN5 and cancer: In a meta-analysis of all pediatric cancer cohorts (GO-CAT, United Kingdom MAGIC and PanCareLIFE), the effect of the TSPAN5 variant remained suggestively significant (OR = 1.6 (95% CI = 1.3–1.9), p = 8.9 × 10−6, I2 = 73.6%).